Stockreport

Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024 [Yahoo! Finance]

Verona Pharma plc - American Depositary Shares  (VRNA) 
US:NASDAQ Investor Relations: nasdaq.com/symbol/vrna/real-time
PDF an investigational, first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: V [Read more]